RAVIMIAMET

Hinnangu kokkuvõte

07.12.2016 anti müügiluba Interchemie Werken De Adelaar Eesti veterinaarravimile Intracox Oral, 25 mg/ml lahus joogivees manustamiseks.

Müügiluba taotleti riikliku protseduuri kaudu.

Tegemist on retseptiravimiga, mida kasutatakse koktsidioosi raviks.

Ravimit Intracox Oral kasutatakse kanadel ja kalkunitel.

Ravimi Intracox Orali toimeaine on toltrasuriil, mis kuulub algloomavastaste ainete rühma.

Ravimile anti müügiluba, kuna Intracox Oral kasutamisest oodatav kasu ületab võimalikud riskid.

Avalik hinnanguaruanne on leitav järgnevatelt lehekülgedelt.

Public Assessment Report

Scientific discussion

INTRACOX ORAL
Toltrazuril

Date: 07.09.2017

This module reflects the scientific discussion for the approval of Intracox Oral. The procedure was finalised at 07.12.2016. For information on changes after this date please refer to the module 'Update'.

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, Estonia has granted a marketing authorisation for Intracox Oral, solution for use in drinking water, 25 mg/ml from the marketing authorisation holder Interchemie Werken De Adelaar Eesti AS. The product is indicated for the treatment of coccidiosis in chicken and turkeys. The product is effective against *Eimeria acervulina*, *Eimeria brunetti*, *Eimeria maxima*, *Eimeria mitis*, *Eimeria necatrix*, *Eimeria tenella*, *Eimeria adenoides* and *Eimeria meleagrimitis*.

A comprehensive description of the indications and posology is given in the SPC.

The marketing authorisation has been granted pursuant to Article 13, generic application of Directive 2001/82/EC. The reference product is Baycox 2,5%, 25 mg/ml, concentrate for oral solution, first authorised in Hungary in February 1994.

II. QUALITY ASPECTS

II.1 Introduction

Intracox Oral is solution for use in drinking water containing 25 mg/ml of toltrazuril.
The product is presented in form of colourless to yellow solution.
Intracox Oral contains the following excipients: trolamine and macrogol 3000.

The product is filled into HDPE bottles of 100 ml and 1000 ml. The bottle is sealed with screw-on HDPE cap.

II.2 2.2 Drug Substance

Toltrazuril is 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxyphenyl]-1,3,5triazinane-2,4,6-trione. Toltrazuril is used to treat outbreaks of coccidiosis in flocks of poultry.
The active substance is manufactured in accordance with the principles of good manufacturing practice. The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.
Stability studies under VICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Veterinary Medicinal Product

The product is presented in form of colourless to yellow solution.
The development of the product has been described, the choice of excipients is justified and their functions explained. Excipients trolamine and macrogol 3000 comply with the current edition of Ph. Eur.
The information provided with regard to manufacturing process of the veterinary medicinal product is considered adequate. Process validation has been carried out and the results are satisfactory. The drug product specifications are considered acceptable. The analytical methods are described and validated. Batch analysis results have been provided.
The product is filled into HDPE bottles of 100 ml and 1000 ml. The bottle is sealed with screw-on HDPE cap.
Stability studies of the finished product have been conducted in accordance with the VICH guideline. The proposed shelf life of 3 years in the original packaging in order to

protect from light were accepted. Shelf life after first opening of the immediate packaging is 90 days and after reconstitution according to directions 24 hours.

III. SAFETY AND RESIDUE ASPECTS

Since the application is made in accordance with Article 13 of Directive 2001/82/EC as amended, for Intracox Oral as a generic of the reference product, Baycox, 2,5%, 25 mg/ml, concentrate for oral solution, pharmacological and toxicological data are not required.
The qualitative and quantitative composition of the test and the reference products are the same in terms of active substance and their pharmaceutical form is also the same. The bioequivalence of the test and reference products was demonstrated in accordance with the relating scientific guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMEA/CVMP/016/00-Rev. 2).

III.1 User Safety

User safety risk assesement is presented in accordance with the guideline (EMEA/CVMP/543/03-Rev.1)
As Intracox Oral has been demonstrated to be bioequivalent with Baycox 2,5%, the potential impact of the active substance in respect of user safety will be the same for both the generic and reference products.
Given the known use of the excipients and their safety profile, it is not expected that the excipients will present a hazard to user.
Warnings and precautions as listed on the product literature reflect those agreed for the reference product and are adequate to ensure safety to users of the product.

III.2 Ecotoxicity/environmental risk assessment (ERA)

The Applicant has submitted a detailed ERA for the product Itracox Oral. Predicted Environmental Concentrations (PEC) were calculated using the method described in the guideline on Environment Impact Assessment (EMEA/CVMP/ERA/418282/2005rev.1). The environmental risk assessment can be stopped at phase I for turkeys. The applicant has presented phase II assessment for chicken.
Based on data provided it is accepted that the use of this product is unlikely to represent an unacceptable risk to the environment when used according to the precautions stated in the SPC in order to minimise any potential risks to the environment.

III.B Residue documentation

MRLs
Toltrazuril is included in Table I of Council Regulation (EEC) No 37/2010, with the following MRLs for poultry species: Muscle: 100 □g/kg
Skin and fat: 200 □g/kg Liver:
600 □g/kg
Kidney: 400 □g/kg

Not for use in animals from which eggs are produced for human consumption.

Withdrawal Periods
Since the application was submitted in accordance with Article 13 of Directive 2001/82/EC as amended, for a generic veterinary product, the same withdrawal periods as approved for the reference product were established: Chicken:
Meat and offal: 16 days.
Turkeys:
Meat and offal: 16 days.
Do not use in birds producing eggs for human consumption.
Do not use in chicken pullets older than 15 weeks of age.

IV. CLINICAL ASPECTS

As this application is submitted in accordance with Article 13 of Directive 2001/82/EC as amended, for a generic veterinary medicinal product, information on the clinical efficacy is not required. The efficacy claims for the generic product are equivalent to those of the reference product.

IV.A Pre-Clinical Aspects

Pharmacokinetics

No data were submitted under this section. Applicant cited the pharmacokinetic data for the reference product.

Pharmacodynamics

No data were submitted under this section. Applicant cited the pharmacodynamic data for the reference product.

IV.B Clinical Aspects

Since this application is submitted in accordance with Article 13 of Directive 2001/82/EC as amended, for a generic veterinary medicinal product, information on the clinical efficacy is not required. The efficacy claims for the generic product are equivalent to those of the reference product.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the safety of the product for humans and the environment is acceptable.